scholarly article | Q13442814 |
P50 | author | Alessandro Fatica | Q32414712 |
Monica Messina | Q52643450 | ||
Francesco Fazi | Q59548158 | ||
Sabina Chiaretti | Q88418165 | ||
P2093 | author name string | Anna Guarini | |
Irene Bozzoni | |||
Ilaria Iosue | |||
Fabrizio Padula | |||
Beatrice Salvatori | |||
Nkerorema Djodji Damas | |||
Arianna Mangiavacchi | |||
P2860 | cites work | Role of the polycomb repressive complex 2 in acute promyelocytic leukemia | Q24309258 |
Widespread microRNA repression by Myc contributes to tumorigenesis | Q24647067 | ||
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model | Q24655262 | ||
The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo | Q24657924 | ||
The proto-oncogene c-myc in hematopoietic development and leukemogenesis | Q28200929 | ||
MYC stimulates EZH2 expression by repression of its negative regulator miR-26a | Q28291303 | ||
MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2 | Q28302211 | ||
Cross talk between microRNA and epigenetic regulation in adult neurogenesis | Q33788417 | ||
c-Myc is a critical target for c/EBPalpha in granulopoiesis. | Q33968356 | ||
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer | Q34268216 | ||
Leukaemogenesis: more than mutant genes | Q34275371 | ||
The roles of FLT3 in hematopoiesis and leukemia | Q34784925 | ||
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells | Q34994576 | ||
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. | Q35561038 | ||
Induction of differentiation in HL60 cells by the reduction of extrachromosomally amplified c-myc | Q35590462 | ||
The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. | Q35804605 | ||
Transcriptional regulation and transformation by Myc proteins | Q36215755 | ||
Cooperating gene mutations in acute myeloid leukemia: a review of the literature. | Q37089717 | ||
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer | Q37198891 | ||
Myc's broad reach | Q37299032 | ||
Mir-214-dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic stem cells | Q37385808 | ||
Role of microRNAs in hematological malignancies | Q37810078 | ||
Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. | Q38343552 | ||
All-trans retinoic acid induces Thrombospondin-1 expression in acute promyelocytic leukemia cells though down-regulation of its transcription repressor, c-MYC oncoprotein | Q39867859 | ||
The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. | Q39877545 | ||
A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia | Q40219227 | ||
c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. | Q40406189 | ||
A new molecular network comprising PU.1, interferon regulatory factor proteins and miR-342 stimulates ATRA-mediated granulocytic differentiation of acute promyelocytic leukemia cells. | Q43609668 | ||
Localization of amplified MYC gene sequences to double minute chromosomes in acute myelogenous leukemia | Q47564321 | ||
Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia | Q80209025 | ||
Role of Myc in differentiation and apoptosis in HL60 cells after exposure to arsenic trioxide or all-trans retinoic acid | Q80812923 | ||
P433 | issue | 5 | |
P921 | main subject | leukemia | Q29496 |
acute myeloid leukemia | Q264118 | ||
P304 | page(s) | 585-592 | |
P577 | publication date | 2011-05-01 | |
P1433 | published in | Genes & Cancer | Q26842471 |
P1476 | title | Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2 | |
P478 | volume | 2 |
Q37357102 | Argonaute 2 sustains the gene expression program driving human monocytic differentiation of acute myeloid leukemia cells. |
Q64962859 | BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells. |
Q36210927 | C/EBPα-p30 protein induces expression of the oncogenic long non-coding RNA UCA1 in acute myeloid leukemia |
Q35651246 | Cellular microRNA miR-26a suppresses replication of porcine reproductive and respiratory syndrome virus by activating innate antiviral immunity |
Q28084911 | Diverse involvement of EZH2 in cancer epigenetics |
Q37183212 | Down-Regulation of Ribosomal S6 kinase RPS6KA6 in Acute Myeloid Leukemia Patients. |
Q26779821 | EZH2 in normal hematopoiesis and hematological malignancies |
Q33610902 | EZH2: not EZHY (easy) to deal. |
Q38509706 | Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia |
Q36178314 | High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells. |
Q36791535 | Identification of linc-NeD125, a novel long non coding RNA that hosts miR-125b-1 and negatively controls proliferation of human neuroblastoma cells |
Q36190268 | Identification of post-transcriptional regulatory networks during myeloblast-to-monocyte differentiation transition |
Q35273569 | MicroRNA-26a promotes anoikis in human hepatocellular carcinoma cells by targeting alpha5 integrin |
Q27013740 | MicroRNA-regulated pathways in hematological malignancies: how to avoid cells playing out of tune |
Q36602853 | MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies |
Q35640345 | Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms |
Q38938169 | New insights into vitamin D anticancer properties: focus on miRNA modulation. |
Q38166375 | Noncoding RNAs in Acute Myeloid Leukemia: From Key Regulators to Clinical Players |
Q38125132 | Polycomb group proteins and MYC: the cancer connection. |
Q64270574 | Pre-clinical evaluation of Minnelide as a therapy for acute myeloid leukemia |
Q58799330 | Recent advances in the understanding and treatment of acute myeloid leukemia |
Q34043370 | Regulation and Role of EZH2 in Cancer |
Q33816240 | RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression |
Q37256443 | Role of MYC in Medulloblastoma. |
Q39556437 | Systematic identification of protein combinations mediating chromatin looping. |
Q90469311 | Targeting of CD38 by the tumor suppressor miR-26a serves as a novel potential therapeutic agent in multiple myeloma |
Q47337952 | Targeting oncoproteins for degradation by small molecules in myeloid leukemia. |
Q26799596 | The Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia Therapy |
Q39202160 | The antihistamines clemastine and desloratadine inhibit STAT3 and c-Myc activities and induce apoptosis in cutaneous T-cell lymphoma cell lines |
Q42063012 | The microRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells. |
Q38796729 | The role of microRNA-26a in human cancer progression and clinical application |
Q39303790 | Upregulation of hsa-miR-125b in HTLV-1 asymptomatic carriers and HTLV-1-associated myelopathy/tropical spastic paraparesis patients |
Q87842370 | We skip to work: alternative splicing in normal and malignant myelopoiesis |
Q37718379 | c-Myc suppresses miR-451⊣YWTAZ/AKT axis via recruiting HDAC3 in acute myeloid leukemia |
Q92761624 | miR-26a promotes hepatocellular carcinoma invasion and metastasis by inhibiting PTEN and inhibits cell growth by repressing EZH2 |
Q35121352 | miR-638 regulates differentiation and proliferation in leukemic cells by targeting cyclin-dependent kinase 2 |
Search more.